CAR T-cell therapy costs can be reduced through cheaper viral vector production and optimized cell harvesting.

“well we reduce the cost by several ways one is that we um basically we've learned to make the virus much in a much cheaper way we've reduced the cost of uh you know the the patent burden um by essentially I I I think by really making successful products and not spending millions of dollars on unsuccessful products so we don't have to recoup all that r d cost um we've changed the machinery um we've changed the way the cells are harvested and finally of course hospital treatment and therapy in India is much cheaper to start off with”